Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma - PubMed
2 months ago
- #Intrahepatic cholangiocarcinoma
- #LATS2
- #Immunotherapy
- LATS2变异（突变和拷贝数缺失）分别在肝内胆管癌（ICC）病例中占3%和34%
- LATS2失活会导致蛋白表达降低、肿瘤复发率增加及ICC患者总体生存率下降
- LATS2失活会抑制Hippo信号通路，导致YAP激活，从而促进免疫逃逸和抗PD-1治疗耐药性
- 该研究表明LATS2可作为ICC精准治疗的潜在生物标志物